Bristol-Myers Squibb Company (NYSE:BMY) Leerink Partners Global Biopharma Conference 2024 Conference Transcript March 13, 2024 10:00 AM ET Executives Samit Hirawat - Executive Vice President, Chief Medical Officer, Head, Development Tim Power - Investor Relations Janet Barth - Investor Relations Analysts Dave Risinger - Leerink Partners Dave Risinger Great. So, good morning, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners and it’s very much my pleasure to welc ...

Bristol-Myers Squibb Company (NYSE:BMY) Leerink Partners Global Biopharma Conference 2024 Conference Transcript March 13, 2024 10:00 AM ET Executives Samit Hirawat - Executive Vice President, Chief Medical Officer, Head, Development Tim Power - Investor Relations Janet Barth - Investor Relations Analysts Dave Risinger - Leerink Partners Dave Risinger Great. So, good morning, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners and it’s very much my pleasure to welc ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2024 on Thursday, April 25, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Investors and the public can register for the live conference call here. Those una ...

5 Top Dividend Stocks Passive Income Investors Should Buy in March jittawit21 / Shutterstock.com Investors love dividend stocks because they provide dependable income and give investors a great opportunity for solid total return. Total return includes interest, capital gains, dividends, and distributions realized over time. In other words, the total return on an investment or a portfolio consists of income and stock appreciation. At 24/7 Wall St., we always remind our readers about the impact total return ...

JHVEPhoto After a period in purgatory, Bristol-Myers Squibb Company (NYSE:BMY) finally returned back into growth mode, though relatively slow. The biopharma has faced a period of excruciating LOEs on key drugs like Revlimid pressuring sales. My investment thesis remains Bullish on the biopharma stock, even after a solid bounce off the lows. Source: Finviz Turnaround Quarter Bristol-Myers just reported a quarter where sales actually returned to growth after a period of 5 quarters with sales dipping YoY. For ...

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $53.28, reflecting a -0.19% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 1.03%. Elsewhere, the Dow saw an upswing of 0.34%, while the tech-heavy Nasdaq appreciated by 1.51%.Shares of the biopharmaceutical company witnessed a gain of 9.75% over the previous month, beating the performance of the Medical sector with its gain of 2.1% and the S&P 500's gain of 3.21%.The upcoming ear ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common type of bladder cancer.1,2 This approval is based on results from the Phase 3 CheckMate –901 trial which evaluated Opdivo in combination with cisplatin and gemcitabine followed by O ...

Solskin Bristol-Myers Squibb Company (NYSE:BMY) has built momentum off its Q4 earnings report which shares up more than 11% in the past month. Compared to a difficult 2023 where the stock lost nearly a third of its value, the recent price action suggests bulls are back alongside an improving fundamental outlook. The story with BMY has been an ongoing shift in its drug portfolio between weaker sales from its legacy brands, balanced by stronger trends from new product launches. Favorably, the outlook is for a ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in March 2024. Samit Hirawat, M.D., executive vice president, chief medical officer, Drug Development, will take part in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida, on Wednesday, March 13, 2024. He will answer questions about the company beginning at 10:00 a.m. ET. Lynelle Hoch, president, Cell Therap ...

If you’re searching for must-have stocks for wealth, look no further. In investing, identifying the right stocks leads to a fear of missing out. Here, in this labyrinth, treasures are unearthed – treasures that may lead to financial abundance. This is a blueprint or guidebook for high-return stocks that yield short-term gains and massive long-term wealth. These stocks are the crème de la crème of the market.From the life-saving pharmaceutical innovations of the first one to the tech juggernaut of the second ...